This is a Phase III, randomized, open-label, multicenter, global study to compare the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd) in combination with durvalumab and carboplatin compared with pembrolizumab in combination with histology-specific platinum-based chemotherapy as first-line treatment of adults with stage IIIB, IIIC, or IV NSCLC without actionable genomic alterations (including sensitizing EGFR mutations, and ALK and ROS1 rearrangements).
2 Primary · 10 Secondary · Reporting Duration: Approximately 4 years
Active Control
Experimental Treatment
1000 Total Participants · 2 Treatment Groups
Primary Treatment: Dato-DXd + Durvalumab + Carboplatin · No Placebo Group · Phase 3
Age 18 - 130 · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: